SCHEMBL1201689

SCHEMBL1201689

Cc1c(O)c(C)c2c(c1O)CC(=O)C(c1ccc(O)c(O)c1)O2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
POLB P06746 2/20 0.40
ALPI P09923 2/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
RECQL P46063 2/20 0.40
BLM P54132 1/20 0.40
MCL1 Q07820 1/20 0.40
ATM Q13315 1/20 0.40
SYNJ2 O15056 2/20 0.39
ALOX5 P09917 2/20 0.38
PTGS2 P35354 1/20 0.38
PTPN1 P18031 1/20 0.36
YWHAG P61981 1/20 0.35
CYP19A1 P11511 2/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
CA12 O43570 1/20 0.34
SLCO2B1 O94956 1/20 0.34
CYP1A1 P04798 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1200431 0.87 PTPN1 (0.45) POLBGAAALOX5PTPN1CYP19A1
SCHEMBL11120384 0.83 MAOA (0.34) KDM4EPOLBMAPTALDH1A1
SCHEMBL11121382 0.83 CDK1 (0.47) GAAMAPTCYP3A4MAPK1
SCHEMBL664145 0.83 ALOX5 (0.39) KDM4EPOLBGAAMAPTRECQL
SCHEMBL11119917 0.81 LMNA (0.40) POLBMAPTRECQLCYP19A1CYP1A1
SCHEMBL7045176 0.81 ESR1 (0.34) GAAMAPTRECQLESR1ESR2
SCHEMBL10606553 0.78 AR (0.35) POLBMAPTCYP3A4
SCHEMBL10607710 0.74 KDM4E (0.45) KDM4EPOLBALPIGAAMAPT
SCHEMBL8249167 0.72 KDM4E (0.54) KDM4EPOLBALPIGAAMAPT
SCHEMBL2781922 0.72 KDM4E (0.54) KDM4EPOLBALPIGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0122053-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH A FLAVANONE SKELETON AND PROCESS FOR THE PREPARATION OF SAID COMPOUNDS INVERNI DELLA BEFFA S.P.A. (IT) 1989-10-04 EP claimed
US-4636569-A Pharmaceutical compositions containing compounds with a flavanone skeleton, process for the preparation of the said compound and novel compounds obtained INVERNI DELLA BEFFA S.P.A. (IT) 1987-01-13 US claimed
EP-0122053-A2 Pharmaceutical compositions containing compounds with a flavanone skeleton and process for the preparation of said compounds INVERNI DELLA BEFFA S.P.A. (IT) 1984-10-17 EP claimed
EP-2120924-B1 AN ANTI-DIABETIC EXTRACT OF HONEYBUSH ZADEC APS (DK) 2016-03-09 EP disclosed
US-20120251643-A1 ANTI-DIABETIC EXTRACT OF HONEYBUSH ZADEC APS (DK) 2012-10-04 US disclosed
US-20110045108-A1 ANTI-DIABETIC EXTRACT OF HONEYBUSH ZADEC APS (DK) 2011-02-24 US disclosed
EP-2120924-A2 AN ANTI-DIABETIC EXTRACT OF HONEYBUSH Zadec APS (DK) 2009-11-25 EP disclosed
WO-2008110552-A9 AN ANTI-DIABETIC EXTRACT OF HONEYBUSH ZADEC APS (DK) 2008-12-04 WO disclosed
WO-2008110552-A2 AN ANTI-DIABETIC EXTRACT OF HONEYBUSH ZADEC APS (DK) 2008-09-18 WO disclosed
US-20040038914-A1 Flavone/ flavanone derivatives for the systemic treatment and prophlaxis of uv-induced dermatoses KRUTMANN JEAN (DE) 2004-02-26 US disclosed
EP-0122053-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH A FLAVANONE SKELETON AND PROCESS FOR THE PREPARATION OF SAID COMPOUNDS INVERNI DELLA BEFFA S.P.A. (IT) 1989-10-04 EP disclosed
US-4636569-A Pharmaceutical compositions containing compounds with a flavanone skeleton, process for the preparation of the said compound and novel compounds obtained INVERNI DELLA BEFFA S.P.A. (IT) 1987-01-13 US disclosed
EP-0122053-A2 Pharmaceutical compositions containing compounds with a flavanone skeleton and process for the preparation of said compounds INVERNI DELLA BEFFA S.P.A. (IT) 1984-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110045108-A1 ANTI-DIABETIC EXTRACT OF HONEYBUSH IAPP, DPP4, DPP3 KDM4E 1708/4885POLB 2892/4885ALPI 502/4885
US-20120251643-A1 ANTI-DIABETIC EXTRACT OF HONEYBUSH IAPP, DPP4, DPP3 KDM4E 1708/4885POLB 2892/4885ALPI 502/4885
US-20040038914-A1 Flavone/ flavanone derivatives for the systemic treatment and prophlaxis of uv-induced dermatoses COLGALT1, PNN, F2 KDM4E 899/4885POLB 189/4885ALPI 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.